Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.54 |
| ▸ | STING1 | Q86WV6 | 4/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | GMNN | O75496 | 1/20 | 0.45 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.45 |
| ▸ | PI4KA | P42356 | 1/20 | 0.44 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.44 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.42 |
| ▸ | AHCY | P23526 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10047656 | 0.87 | ADORA2A (0.47) | STING1ADORA2AADORA1LMNAGMNN | |
| SCHEMBL31204173 | 0.81 | FGFR1 (0.55) | FGFR1STING1AHCY | |
| SCHEMBL2548099 | 0.80 | ADORA2A (0.44) | FGFR1STING1ADORA2AADORA1LMNA | |
| SCHEMBL20509528 | 0.80 | ALDH1A1 (0.44) | STING1ADORA2AADORA1LMNAGMNN | |
| SCHEMBL20509524 | 0.80 | ALDH1A1 (0.44) | STING1ADORA2AADORA1LMNAGMNN | |
| SCHEMBL20509972 | 0.78 | ALDH1A1 (0.43) | STING1ADORA2AADORA1ALDH1A1AHCY | |
| SCHEMBL20511792 | 0.78 | ALDH1A1 (0.43) | STING1ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL20509492 | 0.78 | ALDH1A1 (0.43) | STING1ADORA2AADORA1ALDH1A1AHCY | |
| SCHEMBL20509963 | 0.78 | ALDH1A1 (0.43) | STING1ADORA2AADORA1ALDH1A1AHCY | |
| SCHEMBL20509497 | 0.78 | ALDH1A1 (0.43) | STING1ADORA2AADORA1ALDH1A1AHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150141375-A1 | Methods of Treating Viral Associated Diseases | CHIMERIX, INC. | 2015-05-21 | — | — | US | disclosed |
| EP-2846788-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | Akron Molecules AG (AT) | 2015-03-18 | — | — | EP | disclosed |
| US-8940313-B2 | Tyrosine-based prodrugs of antiviral agents | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940313-B2 | Tyrosine-based prodrugs of antiviral agents | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2015-01-27 | — | — | US | disclosed |
| WO-2013167743-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | AKRON MOLECULES GMBH (AT) | 2013-11-14 | — | — | WO | disclosed |
| US-20130072458-A1 | Methods of Treating Viral Associated Diseases | CHIMERIX, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20120165295-A1 | Compounds, Compositions and Methods for Treating Ocular Conditions | CHIMERIX, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120164104-A1 | Composition and Methods of Treating Viral Infections and Viral Induced Tumors | CHIMERIX, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20110263535-A1 | TYROSINE-BASED PRODRUGS OF ANTIVIRAL AGENTS | UNIVERSITY OF SOUTHERN CALIFORNIA | 2011-10-27 | — | — | US | disclosed |
| US-20110263535-A1 | TYROSINE-BASED PRODRUGS OF ANTIVIRAL AGENTS | UNIVERSITY OF SOUTHERN CALIFORNIA | 2011-10-27 | — | — | US | disclosed |
| WO-2011133963-A2 | TYROSINE-BASED PRODRUGS OF ANTIVIRAL AGENTS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072458-A1 | Methods of Treating Viral Associated Diseases | HAVCR2, EIF2AK2, TSLP | FGFR1 4116/4885STING1 24/4885ADORA2A 914/4885 |
| US-20120165295-A1 | Compounds, Compositions and Methods for Treating Ocular Conditions | EYA3, EYA2, PDE6C | FGFR1 1923/4885STING1 277/4885ADORA2A 1778/4885 |
| US-20150141375-A1 | Methods of Treating Viral Associated Diseases | HAVCR2, EIF2AK2, TSLP | FGFR1 4116/4885STING1 24/4885ADORA2A 914/4885 |
| US-20120164104-A1 | Composition and Methods of Treating Viral Infections and Viral Induced Tumors | HAVCR2, IRF3, CCL5 | FGFR1 1945/4885STING1 8/4885ADORA2A 754/4885 |
| US-20110263535-A1 | TYROSINE-BASED PRODRUGS OF ANTIVIRAL AGENTS | TYMP, MTAP, TK1 | FGFR1 968/4885STING1 207/4885ADORA2A 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.